The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease
European Journal of Medicinal Chemistry; DOI: 10.1016/j.ejmech.2014.07.090.
Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates
ACS Chemical Neuroscience; DOI: 10.1021/cn500084x.
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
JCI: The Journal of Clinical Investigation; doi:10.1172/JCI72176..
Cu(II) and dopamine bind to α-Synuclein and cause large conformational changes
FEBS Journal; DOI: 10.1111/febs.12817
Extracellular α-Synuclein Leads to Microtubule Destabilization via GSK-3β-Dependent Tau Phosphorylation in PC12 Cells.
PLOS One; DOI: 10.1371/journal.pone.0094259.
Resistance of naturally secreted α-synuclein to proteolysis
FASEB Journal; doi: 10.1096/fj.13-245852.
Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls
PLoS ONE; DOI: 10.1371/journal.pone.0088604.
Molecular Basis for Preventing α-Synuclein Aggregation by a Molecular Tweezer
The Journal of Biological Chemistry; doi: 10.1074/jbc.M113.524520.
Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials
Acta Neuropathol 127, 861–879 (2014). https://doi.org/10.1007/s00401-014-1256-4
Reduced vascular endothelial growth factor and capillary density in the occipital cortex in dementia with Lewy bodies
Brain Pathology, 24: 334-343. https://doi.org/10.1111/bpa.12130